Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22678899 | 0.76 | FFAR3 (0.46) | SMN1; SMN2 | |
| SCHEMBL18505961 | 0.76 | DRD2 (0.30) | — | |
| SCHEMBL3420135 | 0.75 | PIK3CD (0.39) | SMN1; SMN2 | |
| SCHEMBL19504943 | 0.75 | — | — | |
| SCHEMBL19276518 | 0.74 | PARP1 (0.35) | SMN1; SMN2 | |
| SCHEMBL25890396 | 0.73 | — | — | |
| SCHEMBL31481326 | 0.72 | FFAR3 (0.32) | — | |
| SCHEMBL22198689 | 0.71 | MAPK1 (0.35) | SMN1; SMN2 | |
| SCHEMBL19498109 | 0.71 | CRHBP (0.34) | — | |
| SCHEMBL10310053 | 0.71 | DRD2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | SMN1; SMN2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.